News & Analysis as of

Startups Initial Public Offering (IPO) Life Sciences

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Fenwick & West LLP

Silicon Alley: 15 Must-Know Facts about NY's Tech Community

Fenwick & West LLP on

As we countdown to NY Tech Week in just 15 days, here are 15 facts about the city's dynamic tech ecosystem....more

Goodwin

Healthcare Experts See Promising Signs of Rebound in M&A and IPO Activity

Goodwin on

In the second week of January, Goodwin and KPMG convened innovators, practitioners, regulators, and others for our annual symposium on the future of life sciences and healthcare. This marked the fifth year that Goodwin...more

Fenwick & West Life Sciences Group

New Funding Cycle for Digital Health Begins on Cautious Note

For digital health startups, the first two months of this year were a welcome departure from 2022, when high inflation and other economic challenges caused investors to press on the brakes and proceed with caution....more

Orrick, Herrington & Sutcliffe LLP

Deal Flow 3.0: European Venture Capital Deal Term Review 2022

Foreword - Despite a shift to economic headwinds, investors injected more than $95B into the European tech market in 2022, the second-largest amount ever. To see how deal terms changed, Orrick developed new technologies and...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include: • Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more

Fenwick & West LLP

Life Sciences Summit: Biotech IPO Market Shows Signs of Life

Fenwick & West LLP on

As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?  Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more

Fenwick & West Life Sciences Group

Digital Health Faced Headwinds in the First Quarter of 2022

Investors are understandably cautious this year as the Federal Reserve tightens monetary policies and financial markets erased the gains from the last 12 months. Public company investors in sectors with enticing upside—like...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

A&O Shearman

What is driving record levels of fundraising by technology companies?

A&O Shearman on

Technology and life sciences companies overwhelmingly dominated fundraising markets in 2021, beating all previous records for amounts raised....more

Fenwick & West Life Sciences Group

The Most-Funded Year Ever for Digital Health Startups – New Trends, Opportunities Emerge in Q3

At the end of Q3, aggregate funding raised by digital health startups in 2021 surpassed $20 billion. Although 2021 continues to be a record-breaking year for digital health startups, investors gently tapped the breaks in Q3....more

Fenwick & West Life Sciences Group

Rock Health Summit Brings Together Brightest Minds in Digital Health

In the technology sector, entrepreneurs are often told to “move fast and break things.” But breaking things is something that won’t work in healthcare, so, as an alternative, innovators may consider “moving fast and keeping...more

Fenwick & West Life Sciences Group

Life Sciences IPOs, SPACs on the Upswing in H1 2021

Public market investors have offered a warm welcome to life sciences companies so far in 2021. As Fenwick’s recent H1 2021 Going Public Report shows, the pace has picked up as 2021 progresses, with 31 life sciences IPOs in...more

Fenwick & West Life Sciences Group

Midway Through 2021, Digital Health Startups Sprint Past 2020 Records

At the end of Q1 2021, our friends at Rock Health noted the record-breaking $6.7 billion raised by digital health startups and declared the sector “all grown up.” The additional $8 billion raised in the second quarter of this...more

Fenwick & West Life Sciences Group

Q1 2021 Digital Health Startups Set New Investment Record, Led by On-demand Healthcare, Population Health Management and R&D Tech...

Last year the digital health sector smashed all previous records for both fundraising and consumer adoption of novel technologies. So far, 2021 is already on track to outshine last year’s impressive numbers. Digital health...more

Latham & Watkins LLP

Fast Track to IPO: Why Are Series A Startups Snatching Topflight CFOs?

Latham & Watkins LLP on

Startups and scale-ups in Europe’s tech and life sciences sectors have flourished dramatically over the past year, fueled by pandemic-induced demand and a wall of investor cash. Early funding rounds are getting bigger, while...more

Fenwick & West Life Sciences Group

IPO Life Sciences Outlook: COVID-19 Vaccine Innovation Could Boost IPO Numbers to Another Record High

The life sciences sector will likely be one of the major drivers in what some analysts predict as the beginning of the largest economic expansion in recent history. ...more

Wilson Sonsini Goodrich & Rosati

2020 Technology and Life Sciences IPO Report

Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1...more

Fenwick & West Life Sciences Group

Digital Health IPO Class of 2020: How Are They Performing Now?

In prior years, it was almost a foregone conclusion that promising digital health startups would be acquired by other companies before having the opportunity to debut on the public markets. However, that changed in 2019,...more

Fenwick & West Life Sciences Group

Digital Health Investments See Significant Uptick in Q1; Investors Consider COVID-19 Impacts in Coming Months

Despite the changes and uncertainty rippling across the entire venture-backed startup ecosystem, the digital health sector saw its best first quarter since analysts began tracking its performance more than a decade ago,...more

Fenwick & West Life Sciences Group

Key Takeaways from Fenwick’s 2019 Digital Health Investor Summit

Fenwick’s eighth annual Digital Health Investor Summit took place against the backdrop of strong and increasingly diverse investment markets, a focus on clinical validation of digital health tools, and a healthcare system...more

Mayer Brown Free Writings + Perspectives

Healthcare and Tech Remain Strong During Slow IPO Market

US IPO volume has declined by almost a quarter year-over-year, according to EY’s recent Global IPO trends report.  To date, $44.5 billion in proceeds have been raised in 127 IPOs, 23% less than at the end of Q3 2018. The...more

Arnall Golden Gregory LLP

[Webinar] Money, Money, Money: Raising Capital and Exit Transactions for Life Sciences Companies - October 3rd, 12:00 pm ET

Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more

Fenwick & West Life Sciences Group

Life Sciences IPOs Haven’t Slowed in 2019

In our 2018 year-end review of life sciences and tech IPOs, we noted that life sciences offerings totaled 67 raising an average of $133 million while there were 45 technology deals raising an average of more than $380...more

Fenwick & West LLP

Silicon Valley Venture Capital Survey – First Quarter 2019 - Full Analysis

Fenwick & West LLP on

We analyzed the terms of 185 venture financings closed in the first quarter of 2019 by companies headquartered in Silicon Valley. We found that valuation results continued to be strong, with the average price increase in Q1...more

36 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide